Insider Trading May 5, 2026 06:58 PM

MaxLinear Director Daniel Artusi Executes Stock Sale Following RSU Vesting

Insider transaction follows a period of significant share price appreciation and strong fiscal Q1 earnings performance.

By Derek Hwang MXL

Daniel A. Artusi, a member of the board of directors for MaxLinear, Inc. (NASDAQ: MXL), recently completed a series of stock transactions involving both the acquisition and sale of common shares. The activity occurred in early May 2026, following the vesting of restricted stock units. This movement comes amid a period of substantial growth for MaxLinear, which has seen its stock price rise significantly over the last twelve months.

MaxLinear Director Daniel Artusi Executes Stock Sale Following RSU Vesting
MXL

Key Points

  • MaxLinear director Daniel Artusi sold 10,500 shares totaling $825,728 after the vesting of 15,741 RSUs.
  • The company's fiscal Q1 2026 results beat expectations for both EPS ($0.22 vs $0.18) and revenue ($137.2M vs $134.56M).
  • Analyst upgrades from Roth/MKM, Needham, and Stifel highlight strength in the data center and optical interconnect markets.

MaxLinear, Inc. (NASDAQ: MXL) director Daniel A. Artusi has executed a notable transaction involving his holdings in the company. On May 4, 2026, Mr. Artusi sold 10,500 shares of MaxLinear common stock. The sale was conducted at price points ranging from $78.60 to $78.76 per share, resulting in a total transaction value of $825,728.

This divestment followed a recent acquisition of shares earlier in the same month. On May 1, 2026, Mr. Artusi acquired 15,741 shares of MaxLinear common stock at a price of $0.00 per share. This specific transaction was the result of the vesting of restricted stock units (RSUs). These RSUs represent a contingent right to receive one share of common stock for each unit, and all 15,741 RSUs in this award vested on May 1.

Following these combined actions, Mr. Artusi maintains a direct holding of 17,382 shares of MaxLinear common stock. At the time of reporting, the company's stock was trading at $81.64, positioned near its 52-week high of $85.43. The equity has demonstrated exceptional momentum, recording a 668% gain over the preceding year. Despite this growth, market valuation analysis suggests the stock may be overvalued at current levels, given its $7.3 billion market capitalization.


Key Developments and Market Context

The recent insider activity occurs against a backdrop of strong fundamental performance for MaxLinear. The company reported first-quarter fiscal 2026 earnings that exceeded market expectations in several key metrics:

  • Earnings Performance: MaxLinear reported earnings per share (EPS) of $0.22, which was higher than the forecasted amount of $0.18.
  • Revenue Growth: Total revenue for the quarter reached $137.2 million, surpassing the projected $134.56 million.

This financial strength has influenced sentiment among various investment firms. Roth/MKM upgraded the stock from Neutral to Buy, citing robust guidance and revenue results that outpaced consensus. Similarly, Needham upgraded MaxLinear from Hold to Buy, pointing toward increased demand within the data center sector. Stifel has maintained its Buy rating while raising its price target to $49, specifically noting growth in optical interconnects within the Infrastructure segment.


Market Risks and Uncertainties

While the company's trajectory appears positive, certain risks and valuation concerns remain inherent to the current market position:

  • Valuation Risk: Analysis indicates that at its current market capitalization of $7.3 billion, the stock may be trading at an overvalued level.
  • Sector-Specific Dependencies: The company's growth is heavily tied to specific segments such as data center optical interconnects and infrastructure markets.

Risks

  • Potential overvaluation of the stock based on current market capitalization and price levels.
  • Reliance on demand within specific segments like data center infrastructure for continued growth.

More from Insider Trading

SentinelOne CEO Executes $3.55 Million Stock Sale Under Rule 10b5-1 Plan May 5, 2026 Axsome Therapeutics COO Executes $1.08 Million Stock Sale via Pre-Planned Trading Program May 5, 2026 Arcutis Biotherapeutics Director Executes Stock Sale via Pre-Arranged Plan May 5, 2026 Amgen Executive Nancy Grygiel Executes Recent Stock Transactions May 5, 2026 Privia Health CFO Executes Stock Sales Totaling Over $200,000 via Rule 10b5-1 Plan May 5, 2026